SPL-108 mitigates metastasis and chemoresistance in tubo-ovarian carcinoma.

ABSTRACT:

Background

Overcoming the heterogeneous mechanisms of metastasis and chemoresistance will improve outcomes for women with tubo-ovarian carcinomas (TOCs). CD44 expression has been shown to be associated with poor prognosis and advanced disease in TOCs. In addition, studies have shown a link between chemoresistance and CD44 pathways. Given the therapeutic implications of targeting CD44, this manuscript examines the biologic effects of a novel CD44 modulator, SPL-108, in TOCs.

Materials and methods

We assessed the effects of SPL-108 on chemosensitivity and migration in a panel of ovarian cancer cell lines with varied CD44 and MDR1 expression. In vitro experiments (cell viability assay, Western blot analysis, Calcein AM fluorescence assay, and migration assay) were carried out t

SUBMITTER: Lara OD 

PROVIDER: S-EPMC11577183 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature